huN901-DM10901 : ImmunoGen & British Biotch : monoclonal antibody

Second Phase I Study of huN901-DM1/BB-10901 (British Biotech)
Announcement of a second Phase 1 study of huN901-DM1/BB-10901, a novel anti-cancer agent targeted at SCLC that uses a humanized monoclonal antibody to deliver a highly potent chemotherapeutic agent specifically to the site of the tumor. [8/02]